ORMP ORAMED PHARMACEUTICALS INC.: institutional ownership and insider trading
88 funds reported holding $86.1M of ORAMED PHARMACEUTICALS INC. in their latest 13F filings; in Q2 2026 funds net bought $17.1M, with 29 new positions and 8 funds selling out; over the last 12 months insiders bought $0 and sold $1.17M on the open market.
Famous investors holding ORMP
- Renaissance Technologies (Renaissance Technologies): $884K, 0.0% of the portfolio
- Ken Griffin (Citadel Advisors): $320K, 0.0% of the portfolio
- Izzy Englander (Millennium Management): $105K, 0.0% of the portfolio
Largest institutional holders of ORMP
- MERCER GLOBAL ADVISORS INC /ADV — $18.3M
- Aquamarine Financial (Cayman) Ltd — $12.1M
- Gem Investment Advisors, LLC — $9.61M
- BlackRock, Inc. (BLK) — $7.74M
- Murchinson Ltd. — $6.21M
- SB Capital Management Inc — $5.42M
- BML Capital Management, LLC — $4.17M
- BOOTHBAY FUND MANAGEMENT, LLC — $2.78M
- GEODE CAPITAL MANAGEMENT, LLC — $2.41M
- GOLDMAN SACHS GROUP INC (GS, GSCE, GS-PA, GS-PC, GS-PD) — $1.22M
Recent ORMP insider trades
- Oct 1, 2026: Gabay Avraham sold 20,000 shares ($90.2K)
- Oct 1, 2026: Hexter Joshua sold 30,000 shares ($135K)
- Jul 1, 2026: Hexter Joshua sold 137,000 shares ($611K)
- Jul 1, 2026: Gabay Avraham sold 73,360 shares ($331K)
Members of Congress trading ORMP
- Jan 10, 2025: Brad Knott sold $15.0K–$50.0K
5%+ owners
- Aquamarine Financial (Cayman) Ltd: 6.0% (Schedule 13G/A, filed Aug 14, 2026)